CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
IDN-6556 +1 moredrug
Likely dose
IDN-6556 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02077374
NCT02077374Phase 2Completed
CompareCT.gov

A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects With Non-Alcoholic Fatty Liver Disease and Raised Transaminases

Conatus Pharmaceuticals Inc.·interventional·Posted Mar 4, 2014·Updated Aug 30, 2016

In Brief

A Phase 2 clinical trial evaluating IDN-6556 and Placebo for Nonalcoholic Steatohepatitis and Non-alcoholic Fatty Liver Disease. Completed, enrolled 38 participants across 7 sites.

Detailed Summary

The purpose of this study is to determine the safety and efficacy of IDN-6556 compared to placebo in patients with diagnosed fat deposits in their liver (not caused by alcohol) and with abnormal liver tests

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 4, 2014
Enrollment StartMar 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.3 years ago

Interventions

IDN-6556drug

25 mg BID for 28 days

Placeboother

Placebo BID for 28 Days